Back to the atlasDownload source notes

November 6, 2026 — scheduled focused research update

Home · Latest · Milestones

All 32 active condition topics are represented; the retained Sleep hub preserves historical links without duplicate monitoring. Every topic review remains focused and incomplete. Full successful-check dates and baseline flags remain unchanged. All returned pages of the specified registry queries were retrieved; retrieval and publication-metadata discovery are not full clinical appraisal or worldwide no-news determinations. Original publication, event, approval and verification dates remain distinct. Historical baselines, repeated evidence and administrative changes are excluded from news alerts.

Findings

Coverage by topic

Whole-body MRI

Coverage: focused/incomplete. 0 newly recorded entries.

Searches: Read canonical topic and state; extracted saved programs and dated evidence for deduplication. Retrieved all ClinicalTrials.gov discovery pages for the September 5–November 6 last-update overlap, all saved named trial IDs, and EuropePMC publication metadata/abstracts for the same publication-date range. Counts and query URLs are in the audit artifacts. Retrieval is distinct from full clinical appraisal. Appraised HERCULES status and targeted screening evidence; excluded a new DWIBS lung-cancer staging preprint because it concerns diagnosed cancer, not asymptomatic population screening.

Coverage and gaps: focused_incomplete; No complete appraisal of repeated-round mortality, downstream workups, overdiagnosis or all professional guidance. HERCULES retains an April 2025 snapshot and no results.; Worldwide registries beyond ClinicalTrials.gov, every full manuscript and supplement, all safety tables, and original long-form informal sources remain incompletely appraised. Preserve the older full successful-check timestamp.

Informal sources and unresolved claims: Targeted Reddit scan experiences and professional course schedules supplied no selected new outcome rumor. Complete podcasts and delivered talks remain unappraised.

Sources checked:

Galleri and organ-specific cancer screening

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: Read canonical topic and state; extracted saved programs and dated evidence for deduplication. Retrieved all ClinicalTrials.gov discovery pages for the September 5–November 6 last-update overlap, all saved named trial IDs, and EuropePMC publication metadata/abstracts for the same publication-date range. Counts and query URLs are in the audit artifacts. Retrieval is distinct from full clinical appraisal. Appraised the November 4 GRAIL release and new case-only MCED and never-smoker LDCT registrations.

Coverage and gaps: focused_incomplete; No complete breast, colorectal, lung, prostate or cervical screening outcome census. FDA decision not verified; early Q1 2027 is only a new sponsor forecast.; Worldwide registries beyond ClinicalTrials.gov, every full manuscript and supplement, all safety tables, and original long-form informal sources remain incompletely appraised. Preserve the older full successful-check timestamp.

Informal sources and unresolved claims: Targeted original-source and Reddit approval searches yielded repeat panel commentary and the sponsor forecast. Full earnings audio was not reviewed.

Sources checked:

Coverage: focused/incomplete. 7 newly recorded entries.

Searches: Read current scope/state and full topic source corpus, deduplicated705events. ClinicalTrials.gov discovery September 5–November 6: 1231/1231 records across13pages; refreshed43saved named IDs for this topic within176combinedunique IDs. Selected relevant records/results and targeted primary/informal source appraisal.

Coverage and gaps: focused_incomplete; Focused incomplete appraisal. All pages of specified ClinicalTrials.gov discovery were downloaded, plus all176 unique saved named IDs across these ten topics; retrieval does not equal appraisal. Full worldwide literature/non-U.S.-registry, regulatory-label, harms/hold/discontinuation census and original conference/podcast recordings remain incomplete. Preserve full successful-check timestamps and incomplete sleep baseline flags.; Full ATTAIN-J supplement and all new Phase 1/2 mechanism/dose details remain incomplete. No new verified EloraTZP Phase 3 numerical dose disclosure found in refreshed named records. New BGM1812 timing/dosing and oral-zenagamtide initiation date discrepancies remain explicit.

Informal sources and unresolved claims: Original saved ENLIGHTEN6 and SOLIS1 threads reread; individual symptoms, allocation and causation remain unconfirmed. New weekly threads and pipeline Reddit searches sampled; no distinct new attributable aggregate result selected.

Sources checked:

Muscle building and preservation

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: Read current core files, current topic notes, prior focused log and 705-event state; overlap September 5–November 6, prioritizing new November 3–6 disclosures.; Refreshed 13 saved named ClinicalTrials.gov records; retrieved all 26 of 26 discovery records across all pages. Retrieval is not complete clinical appraisal.; Targeted original papers/regulator/sponsor/conference and informal-source follow-up; comparison of materially changed named records against November 3 snapshot.

Coverage and gaps: focused_incomplete; Full COURAGE manuscript, complete BELIEVE withdrawal/function tables and taldefgrobep amended partner/dosing remain incompletely appraised.; Complete worldwide clinical, safety and informal-source appraisal remains unfinished; preserve prior full-success timestamps and baseline flags.

Informal sources and unresolved claims: Revisited the original Cantor transcript claim and Veru sponsor/registry sources. The proposed approximately 4,500-person Phase 3 remains unconfirmed; PLATEAU is a separate Phase 2. Targeted new discussion searches did not establish a distinct new clinical rumor. Full original audio remains unappraised.

Sources checked:

Longevity and healthspan trials

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: Read current scope/state and full topic source corpus, deduplicated705events. ClinicalTrials.gov discovery September 5–November 6: 96/96 records across1pages; refreshed16saved named IDs for this topic within176combinedunique IDs. Selected relevant records/results and targeted primary/informal source appraisal.

Coverage and gaps: focused_incomplete; Focused incomplete appraisal. All pages of specified ClinicalTrials.gov discovery were downloaded, plus all176 unique saved named IDs across these ten topics; retrieval does not equal appraisal. Full worldwide literature/non-U.S.-registry, regulatory-label, harms/hold/discontinuation census and original conference/podcast recordings remain incomplete. Preserve full successful-check timestamps and incomplete sleep baseline flags.; VITAL-H recruitment sources disagree; actual enrollment unknown. TAME funded launch/status and full prospective geroscience baseline remain incomplete. The new transplant study cannot resolve healthy-adult intermittent dosing.

Informal sources and unresolved claims: Original Vitaei PEARL24month claim reread; no matching primary follow-up verified. New November 4metformin/SGLT2/f , asting Reddit post repeats a narrative review, not a new trial outcome. Podcast corpus incomplete.

Sources checked:

Localized fat removal and cellulite

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: ClinicalTrials.gov paginated discovery September 5–November 6: 218 returned records retrieved over 3 pages; all returned pages retrieved. Incidental broad matches excluded, not complete clinical appraisal.; Saved named registry IDs for topic: 21; all148unique IDs across8topics retrieved without errors.; Precise EuropePMC MED primary-paper discovery September 5–November 6: 6/6 returned records; selective human title/abstract/full-paper appraisal.; Named sponsors/regulators, original indexed Reddit and talk/podcast/transcript searches; dates/source chains and prior findings deduplicated.

Coverage and gaps: focused_incomplete; Focused/incomplete: retrieved records and selective appraisal do not equal complete worldwide trial, paper, regulator, device/procedure, safety or informal-source coverage. Preserve full successful-check timestamps and baseline flags.; CBL-0102 exact doses, matched Chinese primary registry, independent CDE letter and actual enrollment/first dose were not recovered. SUPREME-02 remains not-yet-recruiting in the original Oct20 registry despite Oct29 sponsor enrollment announcement. The sponsor specifies U.S./Canada sites, while registry also lists Australia; active accepting sites cannot be inferred. No new SUPREME Phase 3 efficacy or RZL-012/tesamorelin new-indication result verified.

Informal sources and unresolved claims: Original indexed CBL-514/tesamorelin/cellulite searches sampled. Seller/self-experiment reports excluded; no distinct new attributable development rumor selected. November 15 ObesityWeek combination poster is explicitly preclinical.

Sources checked:

Broad cardiovascular prevention, lipids and screening

Coverage: focused/incomplete. 4 newly recorded entries.

Searches: Read current scope/state and full topic source corpus, deduplicated705events. ClinicalTrials.gov discovery September 5–November 6: 1132/1132 records across12pages; refreshed23saved named IDs for this topic within176combinedunique IDs. Selected relevant records/results and targeted primary/informal source appraisal.

Coverage and gaps: focused_incomplete; Focused incomplete appraisal. All pages of specified ClinicalTrials.gov discovery were downloaded, plus all176 unique saved named IDs across these ten topics; retrieval does not equal appraisal. Full worldwide literature/non-U.S.-registry, regulatory-label, harms/hold/discontinuation census and original conference/podcast recordings remain incomplete. Preserve full successful-check timestamps and incomplete sleep baseline flags.; AHA HORIZON/ZEUS November 7 full reports are still future and not appraised. ZEUS HR.99 (95%CI.88–1.11) was already publicJuly31; correct the Nov3 blanket wording that implies both HRs are missing as clarification, not fresh news. New lepodisiran injection-site PK studyNCT07914738 was appraised as an operational lead, not an outcomes result.

Informal sources and unresolved claims: Targeted HORIZON/ZEUS and gene-editing original-source/informal searches; recent summaries repeat known negative toplines. Full AHAQ&A is future, no leaked results promoted.

Sources checked:

Alzheimer's screening and therapies

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: Read canonical topic and state; extracted saved programs and dated evidence for deduplication. Retrieved all ClinicalTrials.gov discovery pages for the September 5–November 6 last-update overlap, all saved named trial IDs, and EuropePMC publication metadata/abstracts for the same publication-date range. Counts and query URLs are in the audit artifacts. Retrieval is distinct from full clinical appraisal. Appraised new AuTonomy registry outcome and safety tables; deduplicated prior sabirnetug and CTAD announcements.

Coverage and gaps: focused_incomplete; Full AuTonomy SAP, multiplicity and all biomarker tables remain unappraised. A CTIS aggregator reports RO7568282 recruitment while older CT.gov says not yet recruiting; original EU documents not retrieved, so no status event selected.; Worldwide registries beyond ClinicalTrials.gov, every full manuscript and supplement, all safety tables, and original long-form informal sources remain incompletely appraised. Preserve the older full successful-check timestamp.

Informal sources and unresolved claims: Original Longo transcript and Davidson public chapter notes re-opened. No new source-verified AD confirmatory launch or clinical prevention benefit; full paid transcript remains inaccessible.

Sources checked:

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: Read canonical topic and state; extracted saved programs and dated evidence for deduplication. Retrieved all ClinicalTrials.gov discovery pages for the September 5–November 6 last-update overlap, all saved named trial IDs, and EuropePMC publication metadata/abstracts for the same publication-date range. Counts and query URLs are in the audit artifacts. Retrieval is distinct from full clinical appraisal. Appraised original Compass forecast, anonymous-sourced Usona report, original rumor pages and PATCH amblyopia registration.

Coverage and gaps: focused_incomplete; No direct Usona/FDA filing confirmation or public uAspire Phase 3 tables retrieved. Full NEI congress posters, original MDMA interview audio and international registry inventory remain incomplete.; Worldwide registries beyond ClinicalTrials.gov, every full manuscript and supplement, all safety tables, and original long-form informal sources remain incompletely appraised. Preserve the older full successful-check timestamp.

Informal sources and unresolved claims: New Usona filing report stays unconfirmed. An unrelated financial correction does not resolve it. Original Compass 44–81-day thread now renders, closing an attribution gap, while its timing remains unconfirmed.

Sources checked:

Mental-health treatments, SSRIs and newer antidepressants

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: Read canonical topic and state; extracted saved programs and dated evidence for deduplication. Retrieved all ClinicalTrials.gov discovery pages for the September 5–November 6 last-update overlap, all saved named trial IDs, and EuropePMC publication metadata/abstracts for the same publication-date range. Counts and query URLs are in the audit artifacts. Retrieval is distinct from full clinical appraisal. Appraised HS-10380 and STATRS protocols; screened broad mental-health registry and publication discovery, with LB-102 sponsor context.

Coverage and gaps: focused_incomplete; Not every discovery record fully appraised. A November 4 postpartum-esketamine item has no abstract and could be correspondence; no new RCT result inferred. AbbVie transcript lead lacks original audio and full tables. Durable remission, function, relapse and harms inventory incomplete.; Worldwide registries beyond ClinicalTrials.gov, every full manuscript and supplement, all safety tables, and original long-form informal sources remain incompletely appraised. Preserve the older full successful-check timestamp.

Informal sources and unresolved claims: Targeted Reddit discussion was mainly individual experiences or repeated stock commentary. No distinct new attributable drug-development rumor selected; full podcast and talk census incomplete.

Sources checked:

Bone health, joint preservation and cartilage repair

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: Read current core files, current topic notes, prior focused log and 705-event state; overlap September 5–November 6, prioritizing new November 3–6 disclosures.; Refreshed 20 saved named ClinicalTrials.gov records; retrieved all 140 of 140 discovery records across all pages. Retrieval is not complete clinical appraisal.; Targeted original papers/regulator/sponsor/conference and informal-source follow-up; comparison of materially changed named records against November 3 snapshot.

Coverage and gaps: focused_incomplete; TG-C primary timing/companion result and senolytic osteoporosis original results remain unresolved; full worldwide fracture/healing and joint outcomes review incomplete.; Complete worldwide clinical, safety and informal-source appraisal remains unfinished; preserve prior full-success timestamps and baseline flags.

Informal sources and unresolved claims: Revisited the original secondary TG-C December timing source chain; primary confirmation and original recording remain missing. No companion efficacy result inferred. Conference promotion does not establish new outcomes.

Sources checked:

Liver health and noninvasive assessment

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: Read current scope/state and full topic source corpus, deduplicated705events. ClinicalTrials.gov discovery September 5–November 6: 398/398 records across4pages; refreshed24saved named IDs for this topic within176combinedunique IDs. Selected relevant records/results and targeted primary/informal source appraisal.

Coverage and gaps: focused_incomplete; Focused incomplete appraisal. All pages of specified ClinicalTrials.gov discovery were downloaded, plus all176 unique saved named IDs across these ten topics; retrieval does not equal appraisal. Full worldwide literature/non-U.S.-registry, regulatory-label, harms/hold/discontinuation census and original conference/podcast recordings remain incomplete. Preserve full successful-check timestamps and incomplete sleep baseline flags.; Full new AASLD abstracts/posters, semaglutide/resmetirom comparative RWE and complete cirrhosis/noninvasive test census remain unappraised. September CHMP minutes inaccessible; the new sponsor statement does not prove an EU Wegovy MASH indication or explain the omission.

Informal sources and unresolved claims: Original September 18Wegovy/CHMP post reread; Nov4sponsor statement partly clarifies label context, exactSeptemberprocedure/omission unresolved. AASLD commentary/full interviews not exhaustively appraised.

Sources checked:

Cancer treatment, vaccines and recurrence prevention

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: Read canonical topic and state; extracted saved programs and dated evidence for deduplication. Retrieved all ClinicalTrials.gov discovery pages for the September 5–November 6 last-update overlap, all saved named trial IDs, and EuropePMC publication metadata/abstracts for the same publication-date range. Counts and query URLs are in the audit artifacts. Retrieval is distinct from full clinical appraisal. Appraised FDA HNSCC approval, matching-cohort safety, the recovered October 28 REGAL release and November 4 SLS009 dataset announcement.

Coverage and gaps: focused_incomplete; No complete worldwide oncology or ASH abstract census; SLS009 subgroup denominators, CIs and full original tables remain missing. ALPHA3 November 5 timing lead passed to root for deduplication.; Worldwide registries beyond ClinicalTrials.gov, every full manuscript and supplement, all safety tables, and original long-form informal sources remain incompletely appraised. Preserve the older full successful-check timestamp.

Informal sources and unresolved claims: Original REGAL post and sponsor release reconciled: final-analysis trigger occurrence is confirmed; the exact timing calculation, efficacy and stock-price claims are not.

Sources checked:

Autoimmune disease and immune reset

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: Read current core files, current topic notes, prior focused log and 705-event state; overlap September 5–November 6, prioritizing new November 3–6 disclosures.; Refreshed 23 saved named ClinicalTrials.gov records; retrieved all 75 of 75 discovery records across all pages. Retrieval is not complete clinical appraisal.; Targeted original papers/regulator/sponsor/conference and informal-source follow-up; comparison of materially changed named records against November 3 snapshot.

Coverage and gaps: focused_incomplete; Full ACR ALLO-329 abstract was blocked on direct fetch; indexed text and Nov5 sponsor update do not replace full harms appraisal. Await expanded Nov9 data. GT802 early-human abstract lacks denominators and complete safety.; Complete worldwide clinical, safety and informal-source appraisal remains unfinished; preserve prior full-success timestamps and baseline flags.

Informal sources and unresolved claims: Revisited the original Mount Sinai/Mehandru OncLive planning signal and institution/registry leads. Separate CAR-T enterocolitis research and a Chinese IBD registration do not confirm a Mount Sinai IBD trial. Targeted Reddit discussions mix already recorded safety events and small cohorts, without independent confirmation.

Sources checked:

Non-opioid pain treatments

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: Read current core files, current topic notes, prior focused log and 705-event state; overlap September 5–November 6, prioritizing new November 3–6 disclosures.; Refreshed 15 saved named ClinicalTrials.gov records; retrieved all 1141 of 1141 discovery records across all pages. Retrieval is not complete clinical appraisal.; Targeted original papers/regulator/sponsor/conference and informal-source follow-up; comparison of materially changed named records against November 3 snapshot.

Coverage and gaps: focused_incomplete; CagriSema neuropathy numerical efficacy/harms and identity of proposed Phase 3 novel asset remain undisclosed. New TIPS registry posting was checked against a March 2026 paper; not treated as a newly demonstrated November effect.; Complete worldwide clinical, safety and informal-source appraisal remains unfinished; preserve prior full-success timestamps and baseline flags.

Informal sources and unresolved claims: Targeted Journavx/pain/NaV1.8 discussions and management announcements reviewed. Patient anecdotes do not establish chronic-pain efficacy or label expansion. Original long-form audio remains partial.

Sources checked:

Kidney preservation and earlier detection

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: Read current scope/state and full topic source corpus, deduplicated705events. ClinicalTrials.gov discovery September 5–November 6: 802/802 records across9pages; refreshed25saved named IDs for this topic within176combinedunique IDs. Selected relevant records/results and targeted primary/informal source appraisal.

Coverage and gaps: focused_incomplete; Focused incomplete appraisal. All pages of specified ClinicalTrials.gov discovery were downloaded, plus all176 unique saved named IDs across these ten topics; retrieval does not equal appraisal. Full worldwide literature/non-U.S.-registry, regulatory-label, harms/hold/discontinuation census and original conference/podcast recordings remain incomplete. Preserve full successful-check timestamps and incomplete sleep baseline flags.; APPLAUSE prior-publication/regulatory conversion reconciliation remains incomplete; do not call all numerical results first-ever disclosures. New STARTNCT05405556 posted transplant feasibility results were reviewed as a lower-priority lead: eGFR reporting strategies, not drug-versus-placebo efficacy. Prepare for Kidney Care Nov4Lancet paper remains an unappraised lead; no findings inferred.

Informal sources and unresolved claims: Targeted kidney trial informal searches mainly secondary preprint summaries; no new attributable original rumor selected. Full podcast/transcript search incomplete.

Sources checked:

Hearing and vision preservation/restoration

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: Read canonical topic and state; extracted saved programs and dated evidence for deduplication. Retrieved all ClinicalTrials.gov discovery pages for the September 5–November 6 last-update overlap, all saved named trial IDs, and EuropePMC publication metadata/abstracts for the same publication-date range. Counts and query URLs are in the audit artifacts. Retrieval is distinct from full clinical appraisal. Appraised the fresh AC102 registry and original OPGx-BEST1 milestone; distinguished inherited from acquired sensory loss.

Coverage and gaps: focused_incomplete; No new higher-dose BEST1 efficacy/harms tables. Full common acquired and inherited hearing/vision program inventory unfinished. OCS-01 DIAMOND failure predates the November earnings release and was not relabeled as new.; Worldwide registries beyond ClinicalTrials.gov, every full manuscript and supplement, all safety tables, and original long-form informal sources remain incompletely appraised. Preserve the older full successful-check timestamp.

Informal sources and unresolved claims: Original AC102 purported email re-opened. Registry corroborates the completion component only; conditional 2027 Phase 3/tinnitus programs and efficacy remain unconfirmed.

Sources checked:

Hair loss, restoration and graying

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: ClinicalTrials.gov paginated discovery September 5–November 6: 176 returned records retrieved over 2 pages; all returned pages retrieved. Incidental broad matches excluded, not complete clinical appraisal.; Saved named registry IDs for topic: 28; all148unique IDs across8topics retrieved without errors.; Precise EuropePMC MED primary-paper discovery September 5–November 6: 269/269 returned records; selective human title/abstract/full-paper appraisal.; Named sponsors/regulators, original indexed Reddit and talk/podcast/transcript searches; dates/source chains and prior findings deduplicated.

Coverage and gaps: focused_incomplete; Focused/incomplete: retrieved records and selective appraisal do not equal complete worldwide trial, paper, regulator, device/procedure, safety or informal-source coverage. Preserve full successful-check timestamps and baseline flags.; HCW9302 early three-person efficacy is historical and uncontrolled, not a new November response. Q32 Nov4 repeats Sep30 results and the already saved H1/H2 2027 forecasts; no duplicate alert. PP405 female registry Nov6 update remains not-yet-recruiting with November estimate and no results. Oral-versus-topical minoxidil PMID42957001 remains without quantitative original text; no conclusion from title/secondary story. Xtresse gummy NCT07919782 is a 30-person planned supplement study with unspecified proprietary components, not established new drug efficacy.

Informal sources and unresolved claims: Saved original BQ002, clascoterone and PP405 posts re-opened. BioQ candidate identity remains corroborated, candidate-specific human registration/2027 timing unverified. Cosmo Q1/Q2 2027 filing guidance does not confirm Reddit launch predictions. Newly sampled Nov4 clascoterone discussion repeats unsupported next-year availability/no-side-effects assumptions, not independent evidence.

Sources checked:

Skin aging, laxity and regeneration

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: ClinicalTrials.gov paginated discovery September 5–November 6: 137 returned records retrieved over 2 pages; all returned pages retrieved. Incidental broad matches excluded, not complete clinical appraisal.; Saved named registry IDs for topic: 17; all148unique IDs across8topics retrieved without errors.; Precise EuropePMC MED primary-paper discovery September 5–November 6: 137/137 returned records; selective human title/abstract/full-paper appraisal.; Named sponsors/regulators, original indexed Reddit and talk/podcast/transcript searches; dates/source chains and prior findings deduplicated.

Coverage and gaps: focused_incomplete; Focused/incomplete: retrieved records and selective appraisal do not equal complete worldwide trial, paper, regulator, device/procedure, safety or informal-source coverage. Preserve full successful-check timestamps and baseline flags.; Krystal Nov2 repeats the existing 2027 KB304 Phase 2 forecast, not actual initiation. TrenibotE original audio, actual/accepted FDA resubmission and assigned date remain unverified; transcript only is labeled. DENSITY NCT07919990 retrospectively registers a completed 14-woman uncontrolled RF study with no outcomes. VYC12L NCT07917117 is a new 50-person single-arm observational breast-cancer-survivor hydration/elasticity study; it does not establish skin regeneration or oncologic benefit. All rare-device-harm, skin-tone and comparative-durability data were not fully appraised.

Informal sources and unresolved claims: Named-program interviews, Reddit and podcast leads sampled. October 30 executive timing statement selected with clear transcription/original-audio limitations. Indexed OneSkin/Vonda show notes are older promotional commentary without a new controlled trial or appraised full recording.

Sources checked:

Scar prevention, treatment and stretch marks

Coverage: focused/incomplete. 0 newly recorded entries.

Searches: ClinicalTrials.gov paginated discovery September 5–November 6: 314 returned records retrieved over 4 pages; all returned pages retrieved. Incidental broad matches excluded, not complete clinical appraisal.; Saved named registry IDs for topic: 19; all148unique IDs across8topics retrieved without errors.; Precise EuropePMC MED primary-paper discovery September 5–November 6: 54/54 returned records; selective human title/abstract/full-paper appraisal.; Named sponsors/regulators, original indexed Reddit and talk/podcast/transcript searches; dates/source chains and prior findings deduplicated.

Coverage and gaps: focused_incomplete; Focused/incomplete: retrieved records and selective appraisal do not equal complete worldwide trial, paper, regulator, device/procedure, safety or informal-source coverage. Preserve full successful-check timestamps and baseline flags.; NCT07075159 results first posted Nov5 (10randomized, 5perarm) are not usable as a healing-benefit comparison: primary number-with-dehiscence row says5/5each despite zero reported AEs; secondary gives number assessed (5/5) rather than POSAS scores. Clarification required; do not interpret as all healed or all harmed. NCT07919964 retrospectively registers a 20-person completed split-body microneedling/exosome study: fixed right-side exosomes, no posted results/verified product identity. NCT07922616 retrospectively registers a completed30-person split-lesion metformin/TAC keloid study with no results. SCARFREE remains recruiting but October start is still estimated; actual dose unverified.

Informal sources and unresolved claims: Original verteporfin Reddit status post re-opened; older compassionate/off-label case descriptions and animal findings do not constitute registered-trial efficacy. EU aggregation still differs from CT.gov; original EU documents and investigator audio not fully appraised. No selected new specific rumor.

Sources checked:

Facial volume restoration and contour

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: ClinicalTrials.gov paginated discovery September 5–November 6: 158 returned records retrieved over 2 pages; all returned pages retrieved. Incidental broad matches excluded, not complete clinical appraisal.; Saved named registry IDs for topic: 12; all148unique IDs across8topics retrieved without errors.; Precise EuropePMC MED primary-paper discovery September 5–November 6: 25/25 returned records; selective human title/abstract/full-paper appraisal.; Named sponsors/regulators, original indexed Reddit and talk/podcast/transcript searches; dates/source chains and prior findings deduplicated.

Coverage and gaps: focused_incomplete; Focused/incomplete: retrieved records and selective appraisal do not equal complete worldwide trial, paper, regulator, device/procedure, safety or informal-source coverage. Preserve full successful-check timestamps and baseline flags.; rhPDGF under-eye protocol contains differing blinding descriptions; no effect/safety outcome yet. Saypha FDA authorization/indication verified separately from actual availability; PAS is uncontrolled and not yet recruiting. HA-coated-thread NCT07916103 retrospectively registers completed2024–25study with no results; material biomarker or volume-regeneration effects cannot be inferred. Whole rare vascular-harm, fat-transfer retention and post-weight-loss series census unfinished.

Informal sources and unresolved claims: Original indexed Reddit/filler, grafting and injectable discussions plus professional-interview leads sampled. Personal retention experiences and promotional procedure claims not treated as formal new outcomes; no selected new rumor. Original recordings remain partial.

Sources checked:

Pigmentation and uneven skin tone

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: ClinicalTrials.gov paginated discovery September 5–November 6: 85 returned records retrieved over 1 pages; all returned pages retrieved. Incidental broad matches excluded, not complete clinical appraisal.; Saved named registry IDs for topic: 17; all148unique IDs across8topics retrieved without errors.; Precise EuropePMC MED primary-paper discovery September 5–November 6: 202/202 returned records; selective human title/abstract/full-paper appraisal.; Named sponsors/regulators, original indexed Reddit and talk/podcast/transcript searches; dates/source chains and prior findings deduplicated.

Coverage and gaps: focused_incomplete; Focused/incomplete: retrieved records and selective appraisal do not equal complete worldwide trial, paper, regulator, device/procedure, safety or informal-source coverage. Preserve full successful-check timestamps and baseline flags.; Full STOP-V main report appraised; not all supplementary individual safety tables or full multiplicity hierarchy independently reanalyzed. No cross-trial ranking or JAK-class safety equivalence. TEV53408 new combinedprogram has undisclosed numerical dose/frequency and no human outcomes. EB06 Nov6 registry still recruiting; source update alone is not new initiation. Whole international melasma/PIH/solar-lentigine and oral-JAK regulator census unfinished.

Informal sources and unresolved claims: Indexed original vitiligo/melasma Reddit, talk and podcast searches sampled. Older anonymous povorcitinib participant descriptions do not confirm blinded benefit or approval. No new selected attributable rumor or material status transition; full long-form audio remains incomplete.

Sources checked:

Acne and rosacea

Coverage: focused/incomplete. 2 newly recorded entries.

Searches: ClinicalTrials.gov paginated discovery September 5–November 6: 83 returned records retrieved over 1 pages; all returned pages retrieved. Incidental broad matches excluded, not complete clinical appraisal.; Saved named registry IDs for topic: 16; all148unique IDs across8topics retrieved without errors.; Precise EuropePMC MED primary-paper discovery September 5–November 6: 192/192 returned records; selective human title/abstract/full-paper appraisal.; Named sponsors/regulators, original indexed Reddit and talk/podcast/transcript searches; dates/source chains and prior findings deduplicated.

Coverage and gaps: focused_incomplete; Focused/incomplete: retrieved records and selective appraisal do not equal complete worldwide trial, paper, regulator, device/procedure, safety or informal-source coverage. Preserve full successful-check timestamps and baseline flags.; BMX010 only six uncontrolled participants; randomizedPartBneverstarted. AURORA Nov5 registry remains recruiting and source update does not add new efficacy or actual first-dose day. NCT07919886 Botox+fractionalCO2 inflammatory-acne protocol and NCT07918001 observationalKlenzitC registry are leads without outcomes; no all-rosacea ocular/flushing/vessel or resistance census. Canadian Reddit trial link not fully reconciled to primary national-registry protocol; no generalized mechanism assertion accepted.

Informal sources and unresolved claims: Original Oct7 Ontario recruitment post re-opened; it claims phase 2 and speculates about IL17/JAK mechanisms without a verified matched protocol in this check. Nov3 saved SouthFlorida HOCl IRB lead remains an identification gap. No new selected rumor; denifanstat firstdose source already saved, not inferred from chat.

Sources checked:

Dental alignment, regeneration and repair

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: ClinicalTrials.gov paginated discovery September 5–November 6: 162 returned records retrieved over 2 pages; all returned pages retrieved. Incidental broad matches excluded, not complete clinical appraisal.; Saved named registry IDs for topic: 23; all148unique IDs across8topics retrieved without errors.; Precise EuropePMC MED primary-paper discovery September 5–November 6: 352/352 returned records; selective human title/abstract/full-paper appraisal.; Named sponsors/regulators, original indexed Reddit and talk/podcast/transcript searches; dates/source chains and prior findings deduplicated.

Coverage and gaps: focused_incomplete; Focused/incomplete: retrieved records and selective appraisal do not equal complete worldwide trial, paper, regulator, device/procedure, safety or informal-source coverage. Preserve full successful-check timestamps and baseline flags.; Printedretainer record is retrospective completedstudy without outcomes. AIsegmentation NCT07919652 measures scan accuracy/processingtime (155actual), not clinicalbitequality or total treatmentduration; noresults. Discision NCT07920276 (24planned, randomizedsplitmouth) measures canine movement10weeks, not whole-course/root/gum/relapse outcomes; registrationretrospective and noresults. Toregem index still leads Oct20exhibitionnews; no verified newTRG035dose or human toothregrowth outcome. Directprinted/shape-memory and safety follow-up internationalcensus incomplete.

Informal sources and unresolved claims: Toregem originalindex and indexed orthodontic/dentalregeneration podcasts/talks sampled. Older CandidPro/podcastdescriptions concern planning/monitoring, not newly reported controlled whole-course benefit. Original audio/Japan registry appraisal remains unfinished; no new selected availability rumor.

Sources checked:

Allergy and airway disease

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: Read current core files, current topic notes, prior focused log and 705-event state; overlap September 5–November 6, prioritizing new November 3–6 disclosures.; Refreshed 31 saved named ClinicalTrials.gov records; retrieved all 525 of 525 discovery records across all pages. Retrieval is not complete clinical appraisal.; Targeted original papers/regulator/sponsor/conference and informal-source follow-up; comparison of materially changed named records against November 3 snapshot.

Coverage and gaps: focused_incomplete; ETH47 full protocol/publication and statistical primary-endpoint test deferred/unavailable. No full global food-allergy/asthma/CRS efficacy/safety appraisal; routine record-date changes do not establish new results.; Complete worldwide clinical, safety and informal-source appraisal remains unfinished; preserve prior full-success timestamps and baseline flags.

Informal sources and unresolved claims: Targeted asthma/COPD/allergy informal searches yielded publicity and patient discussion; no distinct new source-grounded rumor selected. ETH47 numerical trends remain sponsor evidence, not independent testimony. Full podcasts/talks remain unappraised.

Sources checked:

Infectious-disease prevention and treatment

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: Read current core files, current topic notes, prior focused log and 705-event state; overlap September 5–November 6, prioritizing new November 3–6 disclosures.; Refreshed 31 saved named ClinicalTrials.gov records; retrieved all 1343 of 1343 discovery records across all pages. Retrieval is not complete clinical appraisal.; Targeted original papers/regulator/sponsor/conference and informal-source follow-up; comparison of materially changed named records against November 3 snapshot.

Coverage and gaps: focused_incomplete; Broad query contains unrelated oncology/dental/other drug records. Novel-antibiotic manuscripts, all global registers and full phage workshop conclusions remain incompletely appraised. DSTA4637S paper and WCK6777 were surfaced as leads but not fully appraised; no efficacy claims added.; Complete worldwide clinical, safety and informal-source appraisal remains unfinished; preserve prior full-success timestamps and baseline flags.

Informal sources and unresolved claims: Revisited Radical Numerics’ original October 20 developer blog and later source chain. The human-administration claim and undisclosed outcomes are already saved under omnii-phage-compassionate-administration; no new evidence or repeated alert. General phage discussions and laboratory AI-model results do not establish clinical benefit.

Sources checked:

Genetic screening and risk prediction

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: Read canonical topic and state; extracted saved programs and dated evidence for deduplication. Retrieved all ClinicalTrials.gov discovery pages for the September 5–November 6 last-update overlap, all saved named trial IDs, and EuropePMC publication metadata/abstracts for the same publication-date range. Counts and query URLs are in the audit artifacts. Retrieval is distinct from full clinical appraisal. Appraised the full SNUseq Baby paper and followed saved PRS, PGT and genomic-screening records.

Coverage and gaps: focused_incomplete; Long-term newborn outcomes, ancestry calibration, all PGT-M/SR/A/P and pharmacogenomic clinical-utility studies remain incomplete. The new trio-WGS diagnostic paper was retrieved at abstract level only.; Worldwide registries beyond ClinicalTrials.gov, every full manuscript and supplement, all safety tables, and original long-form informal sources remain incompletely appraised. Preserve the older full successful-check timestamp.

Informal sources and unresolved claims: Nucleus original whitepaper re-opened; newer social posts repeat the older modeled embryo-score claim. No selected-offspring benefit or new material rumor transition verified.

Sources checked:

Insomnia

Coverage: focused/incomplete. 3 newly recorded entries.

Searches: Read current scope/state and full topic source corpus, deduplicated705events. ClinicalTrials.gov discovery September 5–November 6: 1406/1406 records across15pages; refreshed12saved named IDs for this topic within176combinedunique IDs. Selected relevant records/results and targeted primary/informal source appraisal.

Coverage and gaps: focused_incomplete; Focused incomplete appraisal. All pages of specified ClinicalTrials.gov discovery were downloaded, plus all176 unique saved named IDs across these ten topics; retrieval does not equal appraisal. Full worldwide literature/non-U.S.-registry, regulatory-label, harms/hold/discontinuation census and original conference/podcast recordings remain incomplete. Preserve full successful-check timestamps and incomplete sleep baseline flags.; Complete SOM001 drug identities/doses and design inconsistency, full COMISA methods/PAP background and trial safety tables, complete Avecho video/transcript/interim data and exact trial registration remain gaps. Older small CBTI-versus-zolpidem trial is already baseline, not new from recent coverage.

Informal sources and unresolved claims: Original ENLIGHTEN6/TAK360 fragmentation discussions reread as cross-topic anecdotes. Avecho’s dated CEO-post forecast is sponsor-attributed; full video not reviewed, no invented timestamp.

Sources checked:

Obstructive sleep apnea

Coverage: focused/incomplete. 0 newly recorded entries.

Searches: Read current scope/state and full topic source corpus, deduplicated705events. ClinicalTrials.gov discovery September 5–November 6: 206/206 records across3pages; refreshed13saved named IDs for this topic within176combinedunique IDs. Selected relevant records/results and targeted primary/informal source appraisal.

Coverage and gaps: focused_incomplete; Focused incomplete appraisal. All pages of specified ClinicalTrials.gov discovery were downloaded, plus all176 unique saved named IDs across these ten topics; retrieval does not equal appraisal. Full worldwide literature/non-U.S.-registry, regulatory-label, harms/hold/discontinuation census and original conference/podcast recordings remain incomplete. Preserve full successful-check timestamps and incomplete sleep baseline flags.; AD109 registry tables fromNov3 were deduplicated. ENLIGHTEN OSA and HRS9531 records refreshed; comprehensive worldwide medicine/device/detection comparisons and CV outcomes remain incomplete. Cross-link COMISA RCT once under insomnia.

Informal sources and unresolved claims: Original Mehra October 22interview reread; exploratory menopause subgroup remains without original detailed tables. Registry results do not independently confirm that subgroup account.

Sources checked:

Narcolepsy & excessive sleepiness

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: Read current scope/state and full topic source corpus, deduplicated705events. ClinicalTrials.gov discovery September 5–November 6: 23/23 records across1pages; refreshed9saved named IDs for this topic within176combinedunique IDs. Selected relevant records/results and targeted primary/informal source appraisal.

Coverage and gaps: focused_incomplete; Focused incomplete appraisal. All pages of specified ClinicalTrials.gov discovery were downloaded, plus all176 unique saved named IDs across these ten topics; retrieval does not equal appraisal. Full worldwide literature/non-U.S.-registry, regulatory-label, harms/hold/discontinuation census and original conference/podcast recordings remain incomplete. Preserve full successful-check timestamps and incomplete sleep baseline flags.; DEA/Federal Register live-search route was inaccessible; actual U.S. launch remains unverified. New original Reddit dates are partly index-derived and claims remain unconfirmed. Long-term all-agent outcomes and full SLEEPEurope papers remain incomplete.

Informal sources and unresolved claims: Original u/Tap-Sea and self-identified physician u/StanfordSleepDoc posts reviewed and source-interest disclosed; new specific U.S. launch predictions remain unconfirmed. Original TAK360fragmentation account unchanged.

Sources checked:

Circadian rhythm disorders

Coverage: focused/incomplete. 1 newly recorded entries.

Searches: Read current scope/state and full topic source corpus, deduplicated705events. ClinicalTrials.gov discovery September 5–November 6: 133/133 records across2pages; refreshed5saved named IDs for this topic within176combinedunique IDs. Selected relevant records/results and targeted primary/informal source appraisal.

Coverage and gaps: focused_incomplete; Focused incomplete appraisal. All pages of specified ClinicalTrials.gov discovery were downloaded, plus all176 unique saved named IDs across these ten topics; retrieval does not equal appraisal. Full worldwide literature/non-U.S.-registry, regulatory-label, harms/hold/discontinuation census and original conference/podcast recordings remain incomplete. Preserve full successful-check timestamps and incomplete sleep baseline flags.; Complete preceding90day/older condition baseline and sustained phase/function evidence remain incomplete. Jet-lag hearing schedule is not approval; court outcome unavailable.

Informal sources and unresolved claims: Tasimelteon/Non24/DSPD/shift-work informal-source searches sampled; patient timing experiences do not establish controlled efficacy. Original talk/audio coverage incomplete.

Sources checked:

Restless legs syndrome

Coverage: focused/incomplete. 0 newly recorded entries.

Searches: Read current scope/state and full topic source corpus, deduplicated705events. ClinicalTrials.gov discovery September 5–November 6: 29/29 records across1pages; refreshed8saved named IDs for this topic within176combinedunique IDs. Selected relevant records/results and targeted primary/informal source appraisal.

Coverage and gaps: focused_incomplete; Focused incomplete appraisal. All pages of specified ClinicalTrials.gov discovery were downloaded, plus all176 unique saved named IDs across these ten topics; retrieval does not equal appraisal. Full worldwide literature/non-U.S.-registry, regulatory-label, harms/hold/discontinuation census and original conference/podcast recordings remain incomplete. Preserve full successful-check timestamps and incomplete sleep baseline flags.; CT10/TOMACNCT07397247 remains not yet recruiting in oldFebruary9record despite elapsedApril2026estimated start. Complete long-term augmentation/function, 2026algorithm, iron/device/medicine harms comparison and original recordings remain gaps. No additional material finding selected from appraised sources, not full no-news coverage.

Informal sources and unresolved claims: Original recent RLS/Nidra discussions sampled: benefit, discomfort and insurer/cost anecdotes are individual accounts, not general efficacy or coverage. No distinct development rumor selected.

Sources checked:

Homepage and publication

The October 28 TRANSCEND-T2D-2 featured result was reviewed and retained; its source and selection dates stay unchanged. No endpoint-only data become invented trajectories, and no new clinical estimate is inferred from a forecast or registry stage. Selective development timelines and frontier summaries are reconciled with the new source passages. ZEUS already had its hazard ratio in July; its fuller AHA report is distinct from an unknown HORIZON topline HR.

The public projection removes personal notes, identifying context and private account connections. Release validators and preservation/privacy audits precede publication. No browser QA is claimed. The publication receipt is saved privately after native deployment succeeds; a failure leaves the notebook intact and the web edition explicitly stale.